A PHASE 2B PLACEBO-CONTROLLED, RANDOMIZED STUDY OF A RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE IN PREGNANT WOMEN

NCT04032093

Last updated date
Study Location
East Los Angeles Doctors Hospital
Los Angeles, California, 90023, United States
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Respiratory Tract Infection
Sex
Female
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-49 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Maternal participants:

- Healthy women 18 to 49 years of age between 24 and 36 weeks of gestation on the day of planned vaccination, with an uncomplicated pregnancy, who are at no known increased risk for complications, and whose fetus has no significant abnormalities observed on ultrasound.

- Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.

- Receiving prenatal standard of care.

- Had an ultrasound performed at >=18 weeks of pregnancy.

- Had a negative urinalysis for protein and glucose at the screening visit. Trace protein in the urine is acceptable if the blood pressure is also normal.

- Determined by medical history, physical examination, screening laboratory assessment, and clinical judgment to be appropriate for inclusion in the study.

- Documented negative human immunodeficiency virus antibody, hepatitis B virus surface antigen, hepatitis C virus antibody, and syphilis tests at the screening visit.

- Body mass index of

- Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent document and in this protocol.

- Expected to be available for the duration of the study and willing to give informed consent for her infant to participate in the study.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Infant Participants:


• Infant who is a direct descendant (eg, child or grandchild) of the study personnel.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Respiratory Tract InfectionA Trial to Evaluate the Efficacy and Safety of RSVpreF in Infants Born to Women Vaccinated During Pregnancy.
NCT04424316
  1. Aurora, Colorado
  2. Aurora, Colorado
  3. Aurora, Colorado
  4. Aurora, Colorado
  5. Aurora, Colorado
  6. Aurora, Colorado
  7. Aurora, Colorado
  8. Aurora, Colorado
  9. Birmingham, Alabama
  10. Birmingham, Alabama
  11. Birmingham, Alabama
  12. Birmingham, Alabama
  13. Birmingham, Alabama
  14. Birmingham, Alabama
  15. Birmingham, Alabama
  16. Birmingham, Alabama
  17. Birmingham, Alabama
  18. Mobile, Alabama
  19. Phoenix, Arizona
  20. Phoenix, Arizona
  21. Phoenix, Arizona
  22. Tucson, Arizona
  23. Tucson, Arizona
  24. Chowchilla, California
  25. Huntington Park, California
  26. Huntington Park, California
  27. Lancaster, California
  28. Lancaster, California
  29. Long Beach, California
  30. Long Beach, California
  31. Long Beach, California
  32. Los Angeles, California
  33. Los Angeles, California
  34. Madera, California
  35. Madera, California
  36. Madera, California
  37. Madera, California
  38. Santa Monica, California
  39. Santa Monica, California
  40. Santa Monica, California
  41. Stanford, California
  42. Thousand Oaks, California
  43. Ventura, California
  44. Delta, Colorado
  45. Fruita, Colorado
  46. Grand Junction, Colorado
  47. Grand Junction, Colorado
  48. Grand Junction, Colorado
  49. Grand Junction, Colorado
  50. Grand Junction, Colorado
  51. Montrose, Colorado
  52. Washington, District of Columbia
  53. Washington, District of Columbia
  54. Washington, District of Columbia
  55. Loxahatchee Groves, Florida
  56. Miami, Florida
  57. North Miami Beach, Florida
  58. North Miami Beach, Florida
  59. Panama City, Florida
  60. Panama City, Florida
  61. Panama City, Florida
  62. Panama City, Florida
  63. Pembroke Pines, Florida
  64. Pembroke Pines, Florida
  65. Atlanta, Georgia
  66. Atlanta, Georgia
  67. Atlanta, Georgia
  68. Atlanta, Georgia
  69. Columbus, Georgia
  70. Columbus, Georgia
  71. Blackfoot, Idaho
  72. Blackfoot, Idaho
  73. Blackfoot, Idaho
  74. Idaho Falls, Idaho
  75. Idaho Falls, Idaho
  76. Nampa, Idaho
  77. Nampa, Idaho
  78. Nampa, Idaho
  79. Pocatello, Idaho
  80. Pocatello, Idaho
  81. Fort Wayne, Indiana
  82. Fort Wayne, Indiana
  83. Ames, Iowa
  84. Ames, Iowa
  85. Ames, Iowa
  86. Ames, Iowa
  87. Ankeny, Iowa
  88. West Des Moines, Iowa
  89. West Des Moines, Iowa
  90. El Dorado, Kansas
  91. Kansas City, Kansas
  92. Newton, Kansas
  93. Wichita, Kansas
  94. Wichita, Kansas
  95. Owensboro, Kentucky
  96. Owensboro, Kentucky
  97. Alexandria, Louisiana
  98. Alexandria, Louisiana
  99. Covington, Louisiana
  100. Gretna, Louisiana
  101. Metairie, Louisiana
  102. New Orleans, Louisiana
  103. New Orleans, Louisiana
  104. New Orleans, Louisiana
  105. New Orleans, Louisiana
  106. New Orleans, Louisiana
  107. New Orleans, Louisiana
  108. New Orleans, Louisiana
  109. New Orleans, Louisiana
  110. Slidell, Louisiana
  111. Boston, Massachusetts
  112. Boston, Massachusetts
  113. Blaine, Minnesota
  114. Coon Rapids, Minnesota
  115. Coon Rapids, Minnesota
  116. Coon Rapids, Minnesota
  117. Fridley, Minnesota
  118. Maple Grove, Minnesota
  119. Minneapolis, Minnesota
  120. Minneapolis, Minnesota
  121. Minneapolis, Minnesota
  122. Bay Saint Louis, Mississippi
  123. Gulfport, Mississippi
  124. Saint Louis, Missouri
  125. Butte, Montana
  126. Great Falls, Montana
  127. Helena, Montana
  128. Kalispell, Montana
  129. Missoula, Montana
  130. Grand Island, Nebraska
  131. Hastings, Nebraska
  132. Lincoln, Nebraska
  133. Lincoln, Nebraska
  134. Lincoln, Nebraska
  135. Lincoln, Nebraska
  136. Norfolk, Nebraska
  137. Las Vegas, Nevada
  138. Las Vegas, Nevada
  139. Las Vegas, Nevada
  140. Albuquerque, New Mexico
  141. Albuquerque, New Mexico
  142. East Setauket, New York
  143. East Setauket, New York
  144. East Setauket, New York
  145. Endwell, New York
  146. Johnson City, New York
  147. Mineola, New York
  148. Mineola, New York
  149. Mineola, New York
  150. Mineola, New York
  151. New Hyde Park, New York
  152. Stony Brook, New York
  153. Durham, North Carolina
  154. Durham, North Carolina
  155. Durham, North Carolina
  156. Durham, North Carolina
  157. Dayton, Ohio
  158. Englewood, Ohio
  159. Yukon, Oklahoma
  160. Erie, Pennsylvania
  161. Erie, Pennsylvania
  162. Erie, Pennsylvania
  163. Erie, Pennsylvania
  164. West Reading, Pennsylvania
  165. West Reading, Pennsylvania
  166. West Reading, Pennsylvania
  167. Charleston, South Carolina
  168. Charleston, South Carolina
  169. Greenville, South Carolina
  170. Greenville, South Carolina
  171. Greenville, South Carolina
  172. Summerville, South Carolina
  173. Summerville, South Carolina
  174. Clarksville, Tennessee
  175. Knoxville, Tennessee
  176. Arlington, Texas
  177. Austin, Texas
  178. Beaumont, Texas
  179. Beaumont, Texas
  180. Beaumont, Texas
  181. Beaumont, Texas
  182. Burleson, Texas
  183. Dallas, Texas
  184. Dickinson, Texas
  185. Fort Worth, Texas
  186. Fort Worth, Texas
  187. Galveston, Texas
  188. Georgetown, Texas
  189. Georgetown, Texas
  190. Georgetown, Texas
  191. Georgetown, Texas
  192. Grapevine, Texas
  193. Houston, Texas
  194. Houston, Texas
  195. Houston, Texas
  196. Houston, Texas
  197. Houston, Texas
  198. Houston, Texas
  199. Houston, Texas
  200. Houston, Texas
  201. Lampasas, Texas
  202. Lampasas, Texas
  203. League City, Texas
  204. Longview, Texas
  205. Longview, Texas
  206. Longview, Texas
  207. Longview, Texas
  208. McAllen, Texas
  209. Plano, Texas
  210. San Antonio, Texas
  211. Tomball, Texas
  212. Weatherford, Texas
  213. Murray, Utah
  214. Salt Lake City, Utah
  215. Salt Lake City, Utah
  216. Salt Lake City, Utah
  217. Salt Lake City, Utah
  218. Salt Lake City, Utah
  219. Salt Lake City, Utah
  220. Salt Lake City, Utah
  221. Salt Lake City, Utah
  222. Norfolk, Virginia
  223. Norfolk, Virginia
  224. Richmond, Virginia
  225. Richmond, Virginia
  226. Richmond, Virginia
  227. Richmond, Virginia
  228. Richmond, Virginia
  229. Richmond, Virginia
  230. Richmond, Virginia
  231. Tacoma, Washington
  232. Tacoma, Washington
  233. Tacoma, Washington
  234. Tacoma, Washington
  235. Tacoma, Washington
  236. Huntington, West Virginia
  237. Huntington, West Virginia
  238. Huntington, West Virginia
  239. Santiago, Región Metropolitana
  240. Santiago, Región Metropolitana
  241. Santiago, Región Metropolitana
  242. Helsinki,
  243. Kokkola,
  244. Oulu,
  245. Pori,
  246. Seinajoki,
  247. Tampere,
  248. Turku,
  249. Haarlem,
  250. Hoofddorp,
  251. Utrecht,
  252. Bloemfontein, FREE State
  253. Soshanguve, Gauteng
  254. Santiago de Compostela, A Coruna
  255. Antequera, Malaga
  256. Madrid,
  257. Madrid,
  258. Mostoles,
  259. Valencia,
  260. Kaohsiung,
  261. Taipei,
Female
18 Years+
years
MULTIPLE SITES
Respiratory Tract InfectionA Study to Evaluate the Safety and Immunogenicity of an Adjuvanted RSV Vaccine in Healthy Older Adults
NCT03572062
  1. South Brisbane, Queensland
  2. South Brisbane, Queensland
  3. Geelong, Victoria
  4. Fountain Hills, Arizona
  5. San Diego, California
  6. Coral Gables, Florida
  7. South Miami, Florida
  8. Peoria, Illinois
  9. Fremont, Nebraska
  10. Omaha, Nebraska
  11. Omaha, Nebraska
  12. Rochester, New York
  13. Rochester, New York
  14. South Jordan, Utah
  15. Adamstown, New South Wales
  16. Maroubra, New South Wales
  17. Merewether, New South Wales
  18. Sydney, New South Wales
  19. Sydney, New South Wales
  20. Westmead, New South Wales
  21. Westmead, New South Wales
  22. Sherwood, Queensland
  23. Box Hill, Victoria
  24. Box Hill, Victoria
  25. Camberwell, Victoria
  26. Camberwell, Victoria
  27. Clayton, Victoria
  28. Clayton, Victoria
  29. Geelong, Victoria
  30. Ivanhoe, Victoria
  31. Murdoch, Western Australia
  32. Murdoch, Western Australia
  33. Nedlands, Western Australia
  34. Nedlands, Western Australia
ALL GENDERS
65 Years+
years
MULTIPLE SITES
Respiratory Tract InfectionA PHASE 2B PLACEBO-CONTROLLED, RANDOMIZED STUDY OF A RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE IN PREGNANT WOMEN
NCT04032093
  1. Los Angeles, California
  2. Gretna, Louisiana
  3. Marrero, Louisiana
  4. Metairie, Louisiana
  5. New Orleans, Louisiana
  6. New Orleans, Louisiana
  7. New Orleans, Louisiana
  8. Boston, Massachusetts
  9. Henderson, Nevada
  10. Las Vegas, Nevada
  11. Albuquerque, New Mexico
  12. Albuquerque, New Mexico
  13. Houston, Texas
  14. Houston, Texas
  15. Lampasas, Texas
  16. Longview, Texas
  17. Round Rock, Texas
  18. Salt Lake City, Utah
  19. Salt Lake City, Utah
  20. Richmond, Virginia
  21. San Miguel de Tucuman, Tucuman
  22. Ciudad Autonoma de Buenos Aires,
  23. Cordoba,
  24. Salta,
  25. North Adelaide, South Australia
  26. Birmingham, Alabama
  27. Birmingham, Alabama
  28. Birmingham, Alabama
  29. Cullman, Alabama
  30. Cullman, Alabama
  31. Cullman, Alabama
  32. Phoenix, Arizona
  33. Tucson, Arizona
  34. Tucson, Arizona
  35. Chowchilla, California
  36. Huntington Park, California
  37. Huntington Park, California
  38. Los Angeles, California
  39. Madera, California
  40. Madera, California
  41. Madera, California
  42. Madera, California
  43. Aurora, Colorado
  44. Aurora, Colorado
  45. Aurora, Colorado
  46. Aurora, Colorado
  47. Aurora, Colorado
  48. Aurora, Colorado
  49. Aurora, Colorado
  50. Atlanta, Georgia
  51. Blackfoot, Idaho
  52. Blackfoot, Idaho
  53. Blackfoot, Idaho
  54. Idaho Falls, Idaho
  55. Idaho Falls, Idaho
  56. Idaho Falls, Idaho
  57. Idaho Falls, Idaho
  58. Idaho Falls, Idaho
  59. Idaho Falls, Idaho
  60. Nampa, Idaho
  61. Nampa, Idaho
  62. Nampa, Idaho
  63. Pocatello, Idaho
  64. Pocatello, Idaho
  65. Ankeny, Iowa
  66. West Des Moines, Iowa
  67. West Des Moines, Iowa
  68. El Dorado, Kansas
  69. Hutchinson, Kansas
  70. Alexandria, Louisiana
  71. Metairie, Louisiana
  72. Blaine, Minnesota
  73. Coon Rapids, Minnesota
  74. Coon Rapids, Minnesota
  75. Coon Rapids, Minnesota
  76. Coon Rapids, Minnesota
  77. Minneapolis, Minnesota
  78. Biloxi, Mississippi
  79. Gulfport, Mississippi
  80. Gulfport, Mississippi
  81. Gulfport, Mississippi
  82. Saint Louis, Missouri
  83. Saint Louis, Missouri
  84. Saint Louis, Missouri
  85. Missoula, Montana
  86. Missoula, Montana
  87. Lincoln, Nebraska
  88. Lincoln, Nebraska
  89. Lincoln, Nebraska
  90. Norfolk, Nebraska
  91. Albuquerque, New Mexico
  92. Binghamton, New York
  93. Endwell, New York
  94. Hempstead, New York
  95. Johnson City, New York
  96. Johnson City, New York
  97. Mineola, New York
  98. Mineola, New York
  99. Mineola, New York
  100. Mineola, New York
  101. Rochester, New York
  102. Rochester, New York
  103. Durham, North Carolina
  104. Durham, North Carolina
  105. Durham, North Carolina
  106. Durham, North Carolina
  107. Dayton, Ohio
  108. Dayton, Ohio
  109. Englewood, Ohio
  110. Kettering, Ohio
  111. Summerville, South Carolina
  112. Summerville, South Carolina
  113. Summerville, South Carolina
  114. Beaumont, Texas
  115. Beaumont, Texas
  116. Beaumont, Texas
  117. Beaumont, Texas
  118. Fort Worth, Texas
  119. Fort Worth, Texas
  120. Galveston, Texas
  121. Georgetown, Texas
  122. Georgetown, Texas
  123. Georgetown, Texas
  124. Georgetown, Texas
  125. Houston, Texas
  126. Houston, Texas
  127. Houston, Texas
  128. Houston, Texas
  129. Lampasas, Texas
  130. Longview, Texas
  131. Longview, Texas
  132. McAllen, Texas
  133. Pharr, Texas
  134. Plano, Texas
  135. Plano, Texas
  136. Tomball, Texas
  137. Murray, Utah
  138. Salt Lake City, Utah
  139. Salt Lake City, Utah
  140. Salt Lake City, Utah
  141. Richmond, Virginia
  142. Huntington, West Virginia
  143. Huntington, West Virginia
  144. Huntington, West Virginia
  145. Huntington, West Virginia
  146. San Miguel de Tucuman, Tucuman
  147. Clayton, Victoria
  148. Nedlands, Western Australia
  149. Santiago, Region Metropolitana
  150. Osorno, Región DE LOS Lagos
  151. Santiago, Región Metropolitana
  152. Santiago, Región Metropolitana
  153. Santiago, Región Metropolitana
  154. Santiago, Región Metropolitana
  155. Wellington,
  156. Soweto, Gauteng
Female
18 Years+
years
MULTIPLE SITES
Respiratory Tract InfectionA STUDY OF A RSV VACCINE WHEN GIVEN TOGETHER WITH TDAP IN HEALTHY NONPREGNANT WOMEN AGED BETWEEN 18 TO 49 YEARS
NCT04071158
  1. Stockbridge, Georgia
  2. Honolulu, Hawaii
  3. Wichita, Kansas
  4. Saint Louis, Missouri
  5. Omaha, Nebraska
  6. Oklahoma City, Oklahoma
  7. Warwick, Rhode Island
  8. Dakota Dunes, South Dakota
  9. Austin, Texas
  10. Fort Worth, Texas
  11. Houston, Texas
  12. San Antonio, Texas
  13. San Antonio, Texas
  14. Tomball, Texas
  15. Tomball, Texas
  16. Salt Lake City, Utah
  17. Salt Lake City, Utah
  18. South Jordan, Utah
Female
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE A PHASE 2B PLACEBO-CONTROLLED, RANDOMIZED STUDY OF A RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE IN PREGNANT WOMEN
Official Title  ICMJE A PHASE 2B, RANDOMIZED, PLACEBO-CONTROLLED, OBSERVER-BLINDED TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE IN PREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE AND THEIR INFANTS
Brief Summary This Phase 2b study will evaluate the safety, tolerability, and immunogenicity of an RSV vaccine in pregnant participants who receive either one of 2 dose levels of the vaccine, formulated with or without aluminum hydroxide, or placebo, and investigate safety and characteristics of antibodies in their infants.
Detailed Description This Phase 2b, multicenter, randomized, placebo-controlled study will evaluate the safety, tolerability, and immunogenicity of a respiratory syncytial virus stabilized prefusion F subunit vaccine (RSV vaccine) in pregnant participants who receive either one of 2 dose levels of the vaccine, formulated with or without aluminum hydroxide, or placebo, as well as assess safety and characteristics of transplacentally transferred antibodies in their infants.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description:
This is an observer-blinded study. Study staff dispensing and administering the vaccine will be unblinded, but the participant and all other study personnel, including the principal investigator, will be blinded.
Primary Purpose: Prevention
Condition  ICMJE Respiratory Tract Infection
Intervention  ICMJE
  • Biological: RSV vaccine
    RSV vaccine
  • Biological: Placebo
    Normal saline solution for injection (0.9% sodium chloride injection)
Study Arms  ICMJE
  • Experimental: RSV dose with aluminum hydroxide
    RSV vaccine with aluminum hydroxide
    Intervention: Biological: RSV vaccine
  • Experimental: RSV dose without aluminum hydroxide
    RSV vaccine without aluminum hydroxide
    Intervention: Biological: RSV vaccine
  • Experimental: Higher RSV dose with aluminum hydroxide
    Higher dose level RSV vaccine with aluminum hydroxide
    Intervention: Biological: RSV vaccine
  • Experimental: Higher RSV dose without aluminum hydroxide
    Higher dose level RSV vaccine without aluminum hydroxide
    Intervention: Biological: RSV vaccine
  • Placebo Comparator: Placebo dose
    Normal saline solution for injection (0.9% sodium chloride injection)
    Intervention: Biological: Placebo
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: July 22, 2019)
650
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE November 1, 2021
Estimated Primary Completion Date November 1, 2021   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria - Maternal participants:

  • Healthy women 18 to 49 years of age between 24 and 36 weeks of gestation on the day of planned vaccination, with an uncomplicated pregnancy, who are at no known increased risk for complications, and whose fetus has no significant abnormalities observed on ultrasound.
  • Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
  • Receiving prenatal standard of care.
  • Had an ultrasound performed at >=18 weeks of pregnancy.
  • Had a negative urinalysis for protein and glucose at the screening visit. Trace protein in the urine is acceptable if the blood pressure is also normal.
  • Determined by medical history, physical examination, screening laboratory assessment, and clinical judgment to be appropriate for inclusion in the study.
  • Documented negative human immunodeficiency virus antibody, hepatitis B virus surface antigen, hepatitis C virus antibody, and syphilis tests at the screening visit.
  • Body mass index of </=40 kg/m2 at the time of the screening visit.
  • Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent document and in this protocol.
  • Expected to be available for the duration of the study and willing to give informed consent for her infant to participate in the study.

Inclusion Criteria - Infant Participants:

  • Evidence of a signed and dated ICD signed by the parent(s).
  • Parent(s) willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.

Exclusion Criteria - Maternal Participants:

  • Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection.
  • History of severe adverse reaction associated with a vaccine and/or severe allergic reaction to any component of the investigational product or any related vaccine.
  • History of latex allergy.
  • History of any severe allergic reaction.
  • Participants with known or suspected immunodeficiency.
  • Current pregnancy resulting from in vitro fertilization or other assisted reproductive technology.
  • A prior history of or known current pregnancy complications or abnormalities that will increase the risk associated with the participant's participation in and completion of the study.
  • Major illness of the mother or conditions of the fetus that, in the investigator's judgment, will substantially increase the risk associated with the participant's participation in, and completion of, the study or could preclude the evaluation of the participant's response.
  • Participant with a history of autoimmune disease or an active autoimmune disease requiring therapeutic intervention including but not limited to systemic or cutaneous lupus erythematosus, autoimmune arthritis/rheumatoid arthritis, Guillain-Barré syndrome, multiple sclerosis, Sjögren's syndrome, idiopathic thrombocytopenia purpura, glomerulonephritis, autoimmune thyroiditis, giant cell arteritis (temporal arteritis), psoriasis, and insulin-dependent diabetes mellitus (type 1).
  • Other acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the participant inappropriate for entry into this study.
  • Participation in other studies involving investigational drug(s) within 28 days prior to study entry and/or during study participation.
  • Participants who receive treatment with immunosuppressive therapy including cytotoxic agents or systemic corticosteroids (such as for cancer or an autoimmune disease), or planned receipt of such treatment or agents during study participation. If systemic corticosteroids have been administered short term (<14 days) for treatment of an acute illness, participants should not be enrolled into the study until corticosteroid therapy has been discontinued for at least 30 days before investigational product administration. Inhaled/nebulized, intra articular, intrabursal, or topical (skin or eyes) corticosteroids are permitted.
  • Current alcohol abuse or illicit drug use.
  • Receipt of blood or plasma products or immunoglobulin, from 60 days before investigational product administration, or planned receipt through delivery, with 1 exception, Rho(D) immune globulin (eg, RhoGAM), which can be given at any time.
  • Previous vaccination with any licensed or investigational RSV vaccine or planned receipt during study participation.
  • Laboratory test results at the screening visit outside the normal reference value for pregnant women according to their trimester in pregnancy.
  • Participants who are breastfeeding at the time of the screening visit.

Exclusion Criteria - Infant Participants:

? Infant who is a direct descendant (eg, child or grandchild) of the study personnel.

Sex/Gender  ICMJE
Sexes Eligible for Study:Female
Gender Based Eligibility:Yes
Gender Eligibility Description:Healthy women 18 to 49 years of age who are between 24 and 36 weeks of gestation on the day of planned vaccination, with an uncomplicated pregnancy, who are at no known increased risk for complications, and whose fetus has no significant abnormalities observed on ultrasound
Ages  ICMJE 18 Years to 49 Years   (Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE
Contact: Pfizer CT.gov Call Center1-800-718-1021[email protected]
Listed Location Countries  ICMJE Argentina,   Chile,   New Zealand,   South Africa,   United States
Removed Location Countries Australia
 
Administrative Information
NCT Number  ICMJE NCT04032093
Other Study ID Numbers  ICMJE C3671003
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD:Yes
Plan Description:Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d….
URL:https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d…
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date August 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP